Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation.

Published

Journal Article

Cyclin D2 is a member of the D-type cyclins, implicated in cell cycle regulation, differentiation, and malignant transformation. It was noted previously that cyclin D2 is not expressed in the majority of breast cancer cell lines, whereas abundant expression was detected in finite life span human mammary epithelial cells. By reverse transcription-PCR and Western blot analysis, we extended this finding to primary breast carcinomas and show that the majority of these tumors lack expression of cyclin D2 mRNA (18 of 24) and protein (10 of 13). In contrast, both luminal and myoepithelial subpopulations of normal breast tissues expressed cyclin D2. Hypermethylation of the CpG island in the promoter was detected by methylation-specific PCR in nearly half of the breast cancers (49 of 106) and was associated with silencing of cyclin D2 gene expression. Promoter hypermethylation was also detected in ductal carcinoma in situ, suggesting that loss of cyclin D2 expression is an early event in tumorigenesis. Our results suggest that loss of cyclin D2 expression is associated with the evolution of breast cancer.

Full Text

Duke Authors

Cited Authors

  • Evron, E; Umbricht, CB; Korz, D; Raman, V; Loeb, DM; Niranjan, B; Buluwela, L; Weitzman, SA; Marks, J; Sukumar, S

Published Date

  • March 15, 2001

Published In

Volume / Issue

  • 61 / 6

Start / End Page

  • 2782 - 2787

PubMed ID

  • 11289162

Pubmed Central ID

  • 11289162

International Standard Serial Number (ISSN)

  • 0008-5472

Language

  • eng

Conference Location

  • United States